Prof. Dr. Hojjat Ahmadzadehfar, MSc is head of the Department of Nuclear Medicine at the Westfalen Clinic in Dortmund. Ahmadzadehfar received his medical degree from Guilan Medical University in Iran 1999 and did his residency in Nuclear Medicine in Germany at the Department of Nuclear Medicine, University Hospital Bonn 2003-2008. From 2008 to 2013 he was the assistant medical director of the Department of Nuclear Medicine University Hospital Bonn and from 2013 until end of 2019 worked as the head of the therapy section of the Department of Nuclear Medicine University Hospital Bonn. Prof. Ahmadzadehfar serves as an editor and reviewer for several international journals and has authored and co-authored over 160 papers and book chapters. His main research area is targeted radionuclide therapy and theranostics.

Hans-Jürgen Biersack was Professor of Nuclear Medicine at the University of Bonn for more than 30 years and is now Emeritus Professor. He has many years of experience as Director of the Klinik und Poliklinik für Nuklearmedizin in Bonn. In a long and distinguished career, he has served as President of both the German Society of Nuclear Medicine (1992-4) and the World Federation of Nuclear Medicine and Biology (1994-8). He has received a number of awards, including the Georg von Hevesy Medal (2000), and was Badgastein Lecturer in 1988, Dr. Luis Guerrero Lecturer in 1994, and L. Rao and Shanta Chervu Lecturer in 2000. He holds the Order of Merit from the Federal Republic of Germany and the Sign of Honor from the Red Cross. Professor Biersack has sat on the editorial boards of numerous leading journals and has acted as editor for several journals. He is the author of 440 papers cited in PubMed/MEDLINE as well as 310 book chapters and 35 books. He continues to work at Betaclinic Bonn.

Leonard M.Freeman is the Chief of Service of the Moses Division of Nuclear Medicine at the Montefiore Medical Center as well as Professor of Radiology at the Albert Einstein College of Medicine in New York. He is Board Certified in Radiology, Nuclear Radiology and Nuclear Medicine. He is a graduate of the University of Health Sciences-Chicago Medical School and has received its Outstanding Alumnus Award. He is a past president of the Society of Nuclear Medicine and Molecular Imaging and has received its Distinguished Service Award. He also is a past president of the SNMMI General Clinical Nuclear Medicine Council and has received its Lifetime Achievement Award. Most recently he received the Clinical Best Mentor Award and the Gold Medal of the American College of Nuclear Medicine. He is the author of more than 250 journal articles, scientific exhibits and book chapters. In addition, he is the founder and co-editor of Seminars in Nuclear Medicine for the past 50 years and a past 25 year editor of Nuclear Medicine Annual. He has also edited two major Nuclear Medicine textbooks and has served on the editorial board ofsix journals in related fields. He also is a past examiner for the American Board of Radiology.

Lionel Zuckier is Division Head of Nuclear Medicine at Montefiore Medical Center and Professor of Radiology at the Albert College of Medicine, having relocated from Ottawa, Canada in 2018. He attended medical school in New York at the Albert Einstein College of Medicine where he subsequently continued his training in Nuclear Medicine and Diagnostic Radiology. He has certification from the American Board of Nuclear Medicine, the American Board of Radiology, and the Certification Board of Nuclear Cardiology and is certified as a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) in Nuclear Medicine. He has served on examination committees for both the American Board of Radiology and the Royal College of Physicians and Surgeons of Canada. Dr. Zuckier has published widely in the fields of nuclear medicine and PET and has held basic science and clinical research grants from government and industry. He has served on numerous editorial boards and professional committees, including the American Board of Radiology and the Society of Nuclear Medicine.

Presents the state of the art in diagnostic and therapeutic radionuclide procedures

Focuses on established and emerging clinical applications

Explains the roles of PET/CT, PET/MRI, and SPECT/CT

Considers novel diagnostic tracers and therapeutic radionuclides

Discusses the development of theranostics

Part I: Basics.- Chapter 1. Physics, Instrumentation, and Radiation Safety and Regulations.- Chapter 2. Radiopharmaceutical Sciences.- Chapter 3. Radiomics as applied in Precision medicine.- . Part II: Diagnostic Nuclear Medicine.- Chapter 4. Brain.- Chapter 5. Heart.- Chapter 6. Lung.- Chapter 7. Liver, Spleen and Biliary Tree.- Chapter 8. The Kidney.- Chapter 9. Gastrointestinal System.- Chapter 10. Musculoskeletal System.- Chapter 11. Application of lymphatic mapping and sentinel node biopsy in surgical oncology.- Chapter 12. Lymphoscintigraphy in the management of the lymphatic disorders.- Chapter 13. Neuroendocrine System.- Chapter 14. Thyroid and Parathyroid Imaging.- Chapter 15. Molecular Imaging of Inflammation and Infection.- Chapter 16. Imaging of Atherosclerosis with 18F-FDG PET.- Chapter 17. PET/CT and PET/MRI Imaging, Normal Variations and Artifacts.- Chapter 18. PET in head and neck cancer.- Chapter 19. PET in Gastrointestinal, Pancreatic, and Liver Cancers.- Chapter 20. 18F-FDG-PET/CT in Breast and Gynecologic Cancer.- Chapter 21. PET in lung cancer and mediastinal malignancies.- Chapter 22. MELANOMA.- Chapter 23. PET in Lymphoma.- Chapter 24. PET/CT in renal, bladder and testicular cancer.- Chapter 25. PSMA-ligand imaging in the diagnosis of prostate cancer.- Chapter 26. Miscellaneous.- Chapter 27. Radionuclide imaging of Children.- . PART III: Nuclear Medicine Therapy.- Chapter 28. Radioiodine Therapy for Benign Thyroid Disease.- Chapter 29. Differentiated thyroid cancer: Radioiodine therapy.- Chapter 30. Palliation of metastatic bone pain with radiolabeled phosphonates.- Chapter 31. Radionuclide therapy of bone metastases with radium-223 chloride in prostate cancer patients.- Chapter 32. Peptide Receptor Radionuclide Therapy.- Chapter 33. Treatment of neuroendocrine tumors (neuroblastoma stage III or IV, metastatic pheochromocytoma, etc.) with 131I-mIBG .- Chapter 34. Radioimmunotherapy.- Chapter 35. Radioactive microspheres.- Chapter 36. Radioembolization .- Chapter 37. Assessment of tumor response with MRI and CT after radioembolization.- Chapter 38. Radioisotope Therapy of Malignant Pleural and Peritoneal Effusions.- Chapter 39. Radiosynoviorthesis (Radiation Synovectomy).- Chapter 40. Radioligand Therapy in Prostate Cancer using PSMA-Ligands.